HDACs/EZH2-IN-1

• UNSPSC Description:

  HDACs/EZH2-IN-1 (Compound 22a) is a HDACs/EZH2 inhibitor (EZH2 Y641N inhibition rate at 50 nM: 98%), with selective inhibition against HDAC1 and HDAC6 (IC50: 0.23 μM and 0.07 μM, respectively). HDACs/EZH2-IN-1 exerts a antiproliferative effect on diffuse large B-cell lymphoma cells harboring an EZH2 mutation and on various acute myeloid leukemia cells. HDACs/EZH2-IN-1 has the ability to induce cell differentiation and Apoptosis[1].

• Target Antigen:

  Apoptosis; HDAC; Histone Methyltransferase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage;Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/hdacs-ezh2-in-1.html

• Smiles:

  BrC1=CC(N(CC2CCN(CC2)C3=NC=C(C=N3)C(NO)=O)CC)=C(C(C(NCC4=C(C=C(NC4=O)C)C)=O)=C1)C

• Molecular Weight:

  626.54

• References & Citations:

  [1]Zhang J, et al. Discovery of epigenetic modulators targeting HDACs and EZH2 simultaneously for the treatment of hematological malignancies. Bioorganic chemistry, 2024, 153, 107964.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported